文献速递消化内镜消化道肿瘤与早癌食管胃疾病与幽门螺杆菌

符合筛查条件的初级保健人群中巴雷特食管内镜筛查率低

Low Prevalence of Endoscopic Screening for Barrett's Esophagus in a Screening-Eligible Primary Care Population.
PubMed 文献 · Am J Gastroenterol · 2022-08-12

该回顾性研究纳入64个内科和94个家庭医学诊所网络中符合美国胃肠病学会巴雷特食管筛查标准的1127例患者,仅39%接受食管胃十二指肠镜,巴雷特食管或食管腺癌总患病率为9.9%;症状性胃食管反流病、使用≥1种胃食管反流病药物和家庭医学患者与接受内镜的 odds 升高相关。

要点

  • 符合筛查标准的初级保健患者中仅39%接受了食管胃十二指肠镜。
  • 巴雷特食管或食管腺癌总患病率为9.9%。
  • 因筛查指征转诊的39例中巴雷特食管/食管腺癌患病率为35.1%。

核心结论

  • 在这一大型初级保健人群中,符合筛查条件的患者仅39%接受了食管胃十二指肠镜,多数检查由难治性症状触发而非筛查转诊,凸显改进巴雷特食管筛查传播与实施的必要性。

研究设计与样本

  • 回顾性研究,纳入由美国胃肠病学会巴雷特食管指南定义的筛查合格患者,来自包含64个内科诊所和94个家庭医学诊所的多诊所医疗网络。

主要发现

  • 1127例筛查合格患者平均年龄65.2±8.6岁,45%肥胖,61%吸烟。
  • 73%就诊于家庭医学,94%使用质子泵抑制剂,44%使用≥1种胃食管反流病药物。
  • 仅39%(n=436)患者接受过食管胃十二指肠镜。
  • 巴雷特食管或食管腺癌总体患病率为9.9%。
  • 因筛查为主要指征转诊的39例(9%)中,巴雷特食管/食管腺癌患病率为35.1%。

关键数值与推荐

  • 接受食管胃十二指肠镜 odds 升高的因素:治疗后仍有症状性胃食管反流病(OR 12.1,95%CI 9.1-16.3)、使用≥1种胃食管反流病药物(OR 1.4,95%CI 1.0-1.9)、家庭医学患者(OR 1.5,95%CI 1.1-2.1)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Despite societal recommendations supporting Barrett's esophagus (BE) screening, it is unknown what proportion of eligible patients is screened in primary care. We assessed the proportion of BE screening- eligible patients evaluated in the primary care setting receiving upper esophagogastroduodenoscopy (EGD) and identified factors associated with undergoing EGD. METHODS: This was a retrospective study of BE screening-eligible patients, as defined by the American College of Gastroenterology's BE guidelines, in a multipractice healthcare network consisting of 64 internal medicine practices and 94 family medicine (FM) practices. The proportion undergoing EGD, prevalence of BE and esophageal adenocarcinoma (EAC) in this group, and patient and provider factors associated with undergoing EGD were assessed. Multivariable logistic regression was performed to identify independent predictors of undergoing EGD. RESULTS: Of 1,127 screening-eligible patients, the mean age was 65.2 ± 8.6 years; 45% were obese; and 61% were smokers. Seventy-three percent were seeing FM; 94% were on proton pump inhibitors; and 44% took ≥1 gastroesophageal reflux disease (GERD) medication. Only 39% of patients (n = 436) had undergone EGD. The overall prevalence of BE or EAC was 9.9%. Of 39 (9%) referred for BE screening as the primary indication, BE/EAC prevalence was 35.1%. Factors associated with increased odds of having EGD were symptomatic GERD despite treatment (odds ratio [OR] 12.1, 95% confidence interval [CI] 9.1-16.3), being on ≥1 GERD medication (OR 1.4, 95% CI 1.0-1.9), and being an FM patient (OR 1.5, 95% CI 1.1-2.1). DISCUSSION: In this large, primary care population, only 39% of screening-eligible patients underwent EGD. Most of the examinations were triggered by refractory symptoms rather than screening referrals, highlighting a need for improved dissemination and implementation of BE screening.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Eluri S, Reddy S, Ketchem CC, et al. Low Prevalence of Endoscopic Screening for Barrett's Esophagus in a Screening-Eligible Primary Care Population. Am J Gastroenterol. 2022. PMID: 35971219. doi:10.14309/ajg.0000000000001935

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。